June 13, 2017
After 30 weeks of remedy, Soliqua 100/33 (insulin glargine + lixisenatide injection; Sanofi) lowered HbA1C by 1.09–2.41% in patients with sort 2 diabetes (T2D) beforehand handled with 15–40 Models of basal insulin day by day. Knowledge from the post-hoc evaluation of the LixiLan-L Part three research have been introduced at the American Diabetes Association 77th Scientific Session, San Diego, CA.
The LixiLan-L Part three trial in contrast the effectiveness of Soliqua 100/33 and insulin glargine 100 Models/mL in 736 patients whose T2D was not adequately controlled at screening on 15–40 models of basal insulin every day, alone or mixed with one or two oral anti-diabetic brokers. The post-hoc evaluation included 660 patients who completed the 30-week research period and grouped patients by HbA1C degree at screening: HbA1c ≤eight%, HbA1c >8% to ≤9%, and HbA1c >9%.
Other articles you might like;
- Colour-changing tattoo ink could help people with diabetes
- Scientists reveal THIS technique can make you lose 2.5st in four months – without dieting
- ‘Alexa, what’s my blood sugar level and how much insulin should I take?’
- The Truth Behind Common Apple Cider Vinegar Uses You've Likely Heard Before
- Eating red onions ‘can prevent cancer’ and could protect against diabetes and heart disease